TBPH
TBPH
KYG8807B1068
Theravance Biopharma, Inc.
Loading chart...

Valuation & History

Quarterly trend of key valuation metrics

Metric
Current (TTM) TTM Baseline
Q2 '26 30.06.2026
Q1 '26 31.03.2026
Q4 '25 31.12.2025
Market & Enterprise Value
Market Cap
884.18M EUR
--
--
--
Enterprise Value
535.09M EUR
--
--
--
Valuation Multiples
Trailing P/E
16.38x
--
--
--
Forward P/E
13.36x
--
--
--
Price to Sales
8.48x
--
--
--
Price to Book
3.05x
--
--
--
EV/Revenue
5.13x
--
--
--
EV/EBITDA
48.2x
--
--
--
Price to FCF (P/FCF)
166.8x
--
--
--
EV/FCF
100.94x
--
--
--
FCF Yield
0.6%
--
--
--
ende